Workflow
Cargo Therapeutics(CRGX)
icon
Search documents
What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock
zacks.com· 2024-05-22 17:01
Investors might want to bet on CARGO Therapeutics, Inc. (CRGX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Individual ...
Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High?
zacks.com· 2024-05-22 14:56
CARGO Therapeutics, Inc. (CRGX) closed the last trading session at $20.05, gaining 5.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.33 indicates a 56.3% upside potential. The average comprises three short-term price targets ranging from a low of $30 to a high of $32, with a standard deviation of $1.15. While the lowest estimate indicates an increase of 49.6% from the curren ...
Cargo Therapeutics(CRGX) - 2024 Q1 - Quarterly Report
2024-05-14 20:18
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to ____________ Commission File Number: 001-41859 CARGO Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84-4 ...
Cargo Therapeutics(CRGX) - 2024 Q1 - Quarterly Results
2024-05-14 20:09
Exhibit 99.1 – 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 – - Ongoing follow-up from the Stanford Phase 1 study for firi-cel 1to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival of 25.7 months and favorable safety profile at the dose level selected for CARGO's Phase 2 Study - "We're ...
Cargo Therapeutics(CRGX) - 2023 Q4 - Annual Report
2024-03-21 20:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41859 CARGO Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 84-4080422 (State or other jurisdictio ...
Cargo Therapeutics(CRGX) - 2023 Q4 - Annual Results
2024-03-21 20:10
Financial Performance - CARGO Therapeutics completed an IPO raising approximately $291.0 million in net proceeds[2] - As of December 31, 2023, CARGO had $405.7 million in cash and cash equivalents, expected to fund operations through 2025[11] - Research and development expenses for Q4 2023 were $27.1 million, totaling $75.8 million for the full year[11] - General and administrative expenses for Q4 2023 were $7.9 million, totaling $20.9 million for the full year[12] - The net loss for Q4 2023 was $32.1 million, or $1.49 per share, with a total net loss of $98.1 million for the year, or $16.53 per share[13] - CARGO's total assets increased to $453.0 million as of December 31, 2023, compared to $10.2 million in 2022[17] Clinical Development - The Phase 2 clinical study FIRCE-1 for firi-cel is currently enrolling at 20 sites, with interim results expected in 1H 2025[1][8] - In a Phase 1 study, firi-cel demonstrated a 52% complete response rate in patients with R/R large B-cell lymphoma[9] - The company plans to evaluate firi-cel in earlier stages of disease, including LBCL and other hematologic malignancies[4] Market Position - CARGO was added to the Russell 2000® Index on March 15, 2024[2]
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Newsfilter· 2024-03-21 20:05
– Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 – SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today provided a business update and reported financial results for the quarter and year ending December 3 ...
Cargo Therapeutics(CRGX) - 2023 Q3 - Quarterly Report
2023-12-12 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to ____________ Commission File Number: 001-41859 CARGO Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or ...